Biotech firm Voyager's Q3 collaboration revenue drops, net loss widens

Reuters11-10

Biotech firm Voyager's Q3 collaboration revenue drops, net loss widens

Overview

Voyager Q3 collaboration revenue falls due to lower Novartis agreement revenue
Net loss widens in Q3 2025 due to increased R&D expenses
Company maintains cash runway into 2028 with $229 mln cash position

Outlook

Voyager anticipates VY1706 clinical trial initiation in 2026
Company expects Neurocrine clinical trial initiations in 2026
Voyager maintains cash runway guidance into 2028

Result Drivers

INCREASED R&D EXPENSES - Higher R&D expenses due to MAD clinical trial for VY7523 and tau silencing gene therapy program VY1706

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Collaboration Revenue		$13.37 mln
Q3 Net Income		-$27.89 mln
Q3 Basic EPS		-$0.47
Q3 Operating Income		-$30.59 mln
Q3 Pretax Profit		-$27.81 mln

Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 12 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Voyager Therapeutics Inc is $12.00, about 64.8% above its November 7 closing price of $4.23

Press Release: ID:nGNX79YjJK

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2582718558?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 21:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582718558","market":"us","top_or_hot":-1,"title":"Biotech firm Voyager's Q3 collaboration revenue drops, net loss widens","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Biotech firm Voyager's Q3 collaboration revenue drops, net loss widens</title></head><body><p><span>Overview</span></p><ul><li><p>Voyager Q3 collaboration revenue falls due to lower Novartis agreement revenue</p></li><li><p>Net loss widens in Q3 2025 due to increased R&amp;D expenses</p></li><li><p>Company maintains cash runway into 2028 with $229 mln cash position</p></li></ul><p><span>Outlook</span></p><ul><li><p>Voyager anticipates VY1706 clinical trial initiation in 2026</p></li><li><p>Company expects Neurocrine clinical trial initiations in 2026</p></li><li><p>Voyager maintains cash runway guidance into 2028</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>INCREASED R&amp;D EXPENSES - Higher R&amp;D expenses due to MAD clinical trial for VY7523 and tau silencing gene therapy program VY1706</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Collaboration Revenue</p></td><td></td><td><p>$13.37 mln</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$27.89 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.47</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$30.59 mln</p></td><td></td></tr><tr><td><p>Q3 Pretax Profit</p></td><td></td><td><p>-$27.81 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 12 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/VYGR\">Voyager Therapeutics Inc</a> is $12.00, about 64.8% above its November 7 closing price of $4.23</p></li></ul><p>Press Release: <span>ID:nGNX79YjJK</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biotech firm Voyager's Q3 collaboration revenue drops, net loss widens</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiotech firm Voyager's Q3 collaboration revenue drops, net loss widens\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-10 21:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Biotech firm Voyager's Q3 collaboration revenue drops, net loss widens</title></head><body><p><span>Overview</span></p><ul><li><p>Voyager Q3 collaboration revenue falls due to lower Novartis agreement revenue</p></li><li><p>Net loss widens in Q3 2025 due to increased R&amp;D expenses</p></li><li><p>Company maintains cash runway into 2028 with $229 mln cash position</p></li></ul><p><span>Outlook</span></p><ul><li><p>Voyager anticipates VY1706 clinical trial initiation in 2026</p></li><li><p>Company expects Neurocrine clinical trial initiations in 2026</p></li><li><p>Voyager maintains cash runway guidance into 2028</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>INCREASED R&amp;D EXPENSES - Higher R&amp;D expenses due to MAD clinical trial for VY7523 and tau silencing gene therapy program VY1706</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Collaboration Revenue</p></td><td></td><td><p>$13.37 mln</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$27.89 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.47</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$30.59 mln</p></td><td></td></tr><tr><td><p>Q3 Pretax Profit</p></td><td></td><td><p>-$27.81 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 12 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/VYGR\">Voyager Therapeutics Inc</a> is $12.00, about 64.8% above its November 7 closing price of $4.23</p></li></ul><p>Press Release: <span>ID:nGNX79YjJK</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0154245673.USD","symbol_name":"BNP PARIBAS US MID CAP \"C\" (USD) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nL1N3WM0HW:1","article_id":"2582718558","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582718558","pubTimestamp":1762780142,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Biotech firm Voyager's Q3 collaboration revenue drops, net loss widensOverviewVoyager Q3 collaboration revenue falls due to lower Novartis agreement revenueNet loss widens in Q3 2025 due to increased ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0154245673.USD":"BNP PARIBAS US MID CAP \"C\" (USD) INC","NBIX":"神经分泌生物科学","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","BK4139":"生物科技","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0154245756.USD":"BNP PARIBAS US MID CAP \"C\" (USD) ACC","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","VYGR":"Voyager Therapeutics Inc"},"translate_title":"生物技术公司Voyager第三季度合作收入下降，净亏损扩大","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NBIX":0.9,"VYGR":0.9},"content_text":"Biotech firm Voyager's Q3 collaboration revenue drops, net loss widensOverviewVoyager Q3 collaboration revenue falls due to lower Novartis agreement revenueNet loss widens in Q3 2025 due to increased R&D expensesCompany maintains cash runway into 2028 with $229 mln cash positionOutlookVoyager anticipates VY1706 clinical trial initiation in 2026Company expects Neurocrine clinical trial initiations in 2026Voyager maintains cash runway guidance into 2028Result DriversINCREASED R&D EXPENSES - Higher R&D expenses due to MAD clinical trial for VY7523 and tau silencing gene therapy program VY1706Key DetailsMetricBeat/MissActualConsensus EstimateQ3 Collaboration Revenue$13.37 mlnQ3 Net Income-$27.89 mlnQ3 Basic EPS-$0.47Q3 Operating Income-$30.59 mlnQ3 Pretax Profit-$27.81 mlnAnalyst CoverageThe current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 12 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy.\"Wall Street's median 12-month price target for Voyager Therapeutics Inc is $12.00, about 64.8% above its November 7 closing price of $4.23Press Release: ID:nGNX79YjJKFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582718558","isCrawlerRequest":true}